Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 3;43(32):2475–2489. doi: 10.1038/s41388-024-03094-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A Immunoblots of chromatin-bound fractions prepared from TOV-112D (SLFN11-KO) cells treated with 10 μM olaparib and with or without 50 μM mirin for 0, 6, or 12 h. Blots were probed with the indicated antibodies. B Quantification of data from A. Data were normalized to untreated cells (0 h). Data are means ± standard deviations (n = 3–4, biological replicates). C Representative immunoblots of chromatin-bound fractions prepared from TOV-112D (parent) treated with 10 μM olaparib with or without 50 μM mirin for 0, 6, or 12 h. Blots were probed with the indicated antibodies. D Quantification of data from C. Data were normalized to untreated cells (0 h). Data are means ± standard deviations (n = 3–4, biological replicates). E Immunoblots of whole cell lysates prepared from the indicated TOV-112D cells: siCON or MRE11 siRNA (siMRE11). Blots were probed with the indicated antibodies. F Representative immunoblots of chromatin-bound fractions prepared from TOV-112D (parent) treated with 10 μM olaparib for 0, 6, or 12 h. Blots were probed with the indicated antibodies. G Quantification of data from F. Data were normalized to untreated cells (0 h). Data are means ± standard deviations (n = 7, biological replicates). H Representative immunoblots of whole cell lysates from parent TOV-112D cells treated with 10 μM etoposide or 10 μM olaparib for 0, 3, or 6 h. Blots were probed with the indicated antibodies. I Immunoblots of whole cell lysates prepared from the indicated TOV-112D cells: siCON or CtIP siRNA (siCtIP). Blots were probed with the indicated antibodies. J Representative immunoblots of chromatin-bound fractions prepared from TOV-112D (parent) treated with 10 μM olaparib for 0, 6, or 12 h. Blots were probed with the indicated antibodies. K Quantification of data from J. Data were normalized to untreated cells (0 h). Data are means ± standard deviations (n = 5, biological replicates). NS not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (one-way analysis of variance with Tukey’s post-hoc multiple comparisons test).